

LISTE DES PROJETS ET AIDES AUX JEUNES CHERCHEURS FINANCES PAR L'AFM-TELETHON EN 2016

POLITIQUE D'APPEL D'OFFRES

Projets soumis à l'AO

Commission : Myologie fondamentale

Aides aux jeunes chercheurs post-doctorants

AJURIA ASTOBIZA Leiore, Lyon, France

Deciphering Lamin C regulatory networks during muscle development and autophagy

CHEVALIER Fabien, Ottawa, Canada

Elucidation of Wnt7a mechanism of action for muscle regeneration

ROBERT-PAGANIN Julien, Paris, France

Insights for novel treatment of HCM: structural studies of beta cardiac myosin to understand the impact of HCM mutations and the mechanism of modulators of force generation

Financements de projets Tremplins

GILSON Eric, Nice, France

Role of TRF2, a key telomere complex, in skeletal

RAFFAELLO Anna, Padoue, Italie

Regulation of skeletal muscle mass by a novel muscle-specific alternative splicing isoform of the mitochondrial calcium uniporter activator MICU1

Financements de projets

AMTHOR Helge, Montigny-Le Bretonneux, France

Bone morphogenetic protein-signaling regulates prenatal limb muscle development

BUSCHBECK Marcus, Barcelone, Espagne

How does the histone variant macroH2A regulate muscle metabolism in health and disease?

CHAZAUD Bénédicte, Villeurbanne, France

Macrophage-derived RNaseT2 stimulates myogenic cell fusion and myofiber formation

DE SANTA BARBARA Pascal, Montpellier, France

Function of double-strain RNA-Binding Protein and Collagen during digestive smooth muscle cell plasticity

FASANO Laurent, Marseille, France

Understanding the molecular underpinnings myogenic programs: skeletal versus smooth

FRIEDEN Maud, Genève, Suisse

Triggering human myoblast differentiation: from EGFR to myogenic transcription factors

GILLET Germain, Lyon, France

Role of bcl-2 family proteins on calcium trafficking and cytoskeletal dynamics

HOUDUSSE Anne, Paris, France

Hypertrophic Cardiomyopathy Caused by Myosin Mutations

MAMMUCARI Cristina, Padoue, Italie

Modulation of mitochondrial calcium signaling to combat skeletal muscle atrophy

MASSE Karine, Bordeaux, France

Roles of eya4 protein during somitogenesis

MESSINA Graziella, Milan, Italie

Study of the multiple functions of Nfix in Muscular Dystrophies: a focus on macrophage biology

MUNOZ-CANOVES Pura, Barcelone, Espagne

Understanding muscle stem cell functional decline with aging

- PEREZ RUIZ Ana**, Pampelune, Espagne
Role of proteases in muscular homeostasis and aging
- TAJBAKHSH Shahragim**, Paris, France
Developmental origins and genetic regulation of esophagus skeletal muscles
- VANDEL Laurence**, Toulouse, France
CREB Binding Protein (CBP) co-activator: a new player for mitochondrial (dys)function in myogenesis?

Commission : Bases Moléculaires et Physiopathologie des Dystrophies Musculaires

Aides aux jeunes chercheurs post-doctorants

- HYZEWICZ Janek**, Paris, France
Impact of protein modifications on their interactions and signaling pathways in muscular dystrophies
- KEMALADEWI Dwi**, Toronto, Canada
Elucidating the role of polyamine in laminin-deficient congenital muscular dystrophy
- MOREAU Adrien**, Lyon, France
Development and characterization of a cellular model of a laminopathy based on the cardiac differentiation of patient specific human induced pluripotent stem cells

Financements de projets

- BALSE Elise**, Paris, France
CASK, a new SODium channel partner belonging to the DYstrophin complex: role in heart and skeletal muscle excitability during dystrophinopathies
- BODEGA Béatrice**, Milan, Italie
Epigenetic role for DNA repeats and ncRNAs in FSHD manifestation
- BOZZONI Irene**, Rome, Italie
Role of long non coding RNAs in muscle differentiation and in Duchenne Muscular Dystrophy (DMD)
- BRANCACCIO Andrea**, Milan, Italie
Establishing new models for primary dystroglycanopathies
- BRAND Thomas**, Harefield, Royaume Uni
The genetic interaction of LMNA and POPDC1. Studies of mouse mutants and EDMD and LGMD-1b patients to evaluate the role of POPDC genes as genetic modifiers.
- CHARLET-BERGUERAND Nicolas**, Illkirch, France
Novel animal models of Myotonic Dystrophies
- COSSEE Mireille**, Montpellier, France
High throughput sequencing in patients with myopathy and muscular dystrophy: phenotype-genotype correlations studies, functional analyses of TTN variants, search for novel genes.
- D'ANTONA Giuseppe**, Pavie, Italie
Study of the role of muscle fatigue as predictor of muscle degeneration in facioscapulohumeral muscular dystrophy
- DURBEEJ-HJALT Madeleine**, Lund, Suède
Characterization of metabolic alterations in MDC1A and evaluation of potential therapies to improve muscle structure and function
- JASMIN Bernard**, Ottawa, Canada
Translational Regulation of Utrophin A as a Novel Therapeutic Strategy for DMD
- LACAMPAGNE Alain**, Montpellier, France
Cardiac dysfunction in Duchenne Muscle Dystrophy children: pathophysiological role of type 2 ryanodine receptor
- LE RUMEUR Elisabeth**, Rennes, France
Structure and interactions of dystrophin and their modifications in Becker muscular dystrophy
- MARTELLI Fabio**, San Donato Milanese, Italie
microRNA function and use as biomarkers in Myotonic Dystrophy type 1
- MILLER Jeffrey**, Boston, Etats-Unis
Pathogenesis of congenital muscular dystrophy Type 1A (laminin-alpha-2-deficiency)
- MOREL Véronique**, Lyon, France
Deciphering neuromuscular junction glutamate receptor density control by Msp300/Nesprin1 in drosophila

- PLAISIER Emmanuelle**, Paris, France
Pathogenic role of basement membrane defects and endoplasmic reticulum stress in the myopathy related to COL4A1 HANAC mutations
- RAVEL-CHAPUIS Aymeric**, Ottawa, Canada
Role of Calcium Handling Proteins and Calcineurin Signaling in Myotonic Dystrophy type 1
- RUCCI Nadia**, L'Aquila, Italie
Bone phenotype in Duchenne muscular dystrophy: unveiling the role of LCN2 and implications for therapy
- SANDRI Marco**, Padoue, Italie
Dissecting the retrograde signaling that controls neuromuscular junction
- THORSTEINSDOTTIR Solveig**, Lisbonne, Portugal
Understanding the developmental onset of muscular dystrophy in a mouse model of MDC1A
- TUFFERY-GIRAUD Sylvie**, Montpellier, France
Defining the trans-acting factors that regulate normal DMD pre-messenger RNA splicing: a combination of RNA interference and targeted RNA-seq approaches.
- VAILLEND Cyrille**, Orsay, France
Neurobiology of intellectual disabilities in Duchenne muscular dystrophy: Characterization of the glial dysfunctions due to brain Dp71 loss in mice
- ZAMMIT Peter**, Londres, Royaume-Uni
Dynamic Mapping of Perturbed Signalling Underlying FSHD
- ZAMMIT Peter**, Londres, Royaume-Uni
The Ephrins as mediators of DUX4 toxicity in FSHD
- ZINN-JUSTIN Sophie**, Gif-Sur-Yvette, France
Emerin self-assembly and lamin/BAF binding: impact of emerin missense mutations causing Emery-Dreifuss muscular dystrophy versus isolated cardiac defects

Commission : Bases moléculaires et physiopathologie des autres maladies neuromusculaires

Aides aux jeunes chercheurs post-doctorants

- SAVARESE Marco**, Naples, Italie
Functional validation of rare TTN missense variants
- VIAUD Julien**, Toulouse, France
Role of PtdIns5P and MTM1/Tiam1 interaction in X-linked recessive centronuclear/myotubular myopathy
- YALGIN Cagri**, Tampere, Finlande
Mechanisms by which alternative oxidase ameliorates locomotor deficit due to cytochrome c oxidase deficiency in Drosophila

Financements de projets Tremplins

- MOUILLET-RICHARD Sophie**, Paris, France
Prion protein dysfunction in inherited metabolic myopathies
- STEFFANN Julie**, Paris, France
Does nuclear transfer alter mitochondrial-nuclear cross-talks in the human preimplantation embryo?

Financements de projets

- AUTHIER François Jérôme**, Créteil, France
Myofiber expression of HLA-DR in dysimmune myopathies
- BENDAHHOU Said**, Nice, France
Pathomechanisms in Andersen's syndrome: insights into excitable and non excitable tissues
- BOYER Olivier**, Rouen, France
Oxidative stress: the main pathogenic process in myositis?
- DE LONLAY Pascale**, Paris, France
Investigating the connections between inflammation, cell metabolism and calcium regulation in metabolic rhabdomyolysis to design new therapeutic approaches

- DUFOUR Eric**, Tampere, Finlande
Altering complex I response to OXPHOS dysfunctions; a new tool to combat mitochondrial diseases
- DURIEUX Anne-Cécile**, Saint Priest En Jarez, France
Deepen the pathophysiological mechanisms of the Dynamin 2-associated centronuclear myopathy and combat muscle dysfunction by targeting myostatin
- FERREIRO Ana**, Paris, France
SEPN1-related myopathy: mitochondrial dysfunction as a novel pathophysiological mechanism and therapeutic target
- JACQUEMOND Vincent**, Villeurbanne, France
Phosphoinositides and Ca²⁺ signaling in normal and diseased skeletal muscle
- LETELLIER Thierry**, Toulouse, France
Influence of mtDNA background (haplogroups) on mitochondrial pathologies.
- MERICSKAY Mathias**, Châtenay Malabry, France
Role of Actin-SRF-MRTFA Axis in the development of dilated cardiomyopathy
- METODIEV Metodi**, Paris, France
Abnormal mitochondrial biogenesis and protein maturation in human mitochondrial diseases.
- MITRANI-ROSENBAUM Stella**, Jerusalem, Israël
Characterization of the microRNA profile of GNE Myopathy
- NICOLE Sophie**, Paris, France
Pathophysiology of congenital muscle weakness linked to abnormal neuromuscular excitability
- PRUIJN Ger**, Nijmegen, Pays-Bas
Viral infections and the autoimmune response in inclusion body myositis
- RAVENSCROFT Gianina**, Nedlands, Australie
Neuromuscular disease presenting in utero - gene discovery and pathobiology
- STENZEL Werner**, Berlin, Allemagne
Roles of hypoxia and innate immunity in juvenile and adult dermatomyositis
- TARESTE David**, Paris, France
Unraveling the mode of action of Mitofusins in healthy and pathogenic mitochondrial fusion
- WALLGREN-PETTERSSON Carina**, Helsinki, Finlande
Nemaline myopathy and related disorders: diagnostic methods, disease-gene identification, pathogenesis and genotype-phenotype correlations

Commission : Système nerveux : Motoneurone et jonction neuro-musculaire

Aides aux jeunes chercheurs post-doctorants

- CANO Raquel**, Séville, Espagne
Monitoring synaptic function in the neuromuscular junction of a SMA mouse model which express SypHy-pHluorin
- CIURA Sorana**, Paris, France
Physiological analysis of C9orf72 depletion, a major genetic cause in ALS using zebrafish models
- D'ALESSANDRO Manuela**, Villeurbanne, France
Regulation of muscle acetylcholine receptor expression by novel genes identified in C. elegans genetic screens
- DELESTREE Nicolas**, New York, Etats-Unis
Alteration of the neuromodulatory pathways and their relationship with motor neuron hyperexcitability in Spinal Muscular Atrophy

Financements de projets Tremplins

- BOMONT Pascale**, Montpellier, France
Neurofilaments in Health and Charcot-Marie-Tooth diseases
- MONTEIL Arnaud**, Montpellier, France
Modeling infantile neuroaxonal dystrophy, a nalcn channel-related disorder, in zebrafish
- MOURIER Arnaud**, Bordeaux, France
Metabolic defects caused by Mitofusin 2 loss of function open up new therapeutic strategies for the Charcot-Marie-Tooth type 2A disease

ZAGLIA Tania, Padoue, Italie

Functional assessment of skeletal muscle beta2-adrenoceptor modulation by the catecholaminergic component of motor nerves, explored using in vivo optogenetics and multiphoton imaging

Financements de projets

BESSEREAU Jean-Louis, Villeurbanne, France

Genetic control of acetylcholine receptor expression: from *C. elegans* to mammals

CHARLET-BERGUERAND Nicolas, Illkirch, France

Role of C9ORF72 in amyotrophic lateral sclerosis & frontotemporal dementia

CHRAST Roman, Stockholm, Suède

The role of axonal metabolic changes in the pathophysiology of Charcot-Marie-Tooth disease

CHRISTADOSS Premkumar, League City, Etats-Unis

MuSK specific IgG4 B cells as biomarker for MuSK myasthenia gravis

DEVAL Emmanuel, Valbonne, France

Molecular mechanisms of chronic muscle pain - Focus on Acid-Sensing Ion Channels (ASICs)

DUPUIS Luc, Strasbourg, France

Motor neuron loss triggered by defective nuclear import of RNA-binding proteins: mechanistic studies using FUS as a prototypical example

GALINDO Máximo Ibo, Valence, Espagne

Metabolic and functional characterization of clinically relevant Charcot-Marie-Tooth genotypes in a *Drosophila* model

GREENSMITH Linda, Londres, Royaume-Uni

Targeting molecular pathways of disease in SBMA

HECKMANN Jeannine, Cape Town, Afrique Du Sud

Investigating the Molecular Genetic Basis of treatment-resistant ophthalmoplegia in a subset of Myasthenia Gravis Patients of African-genetic Ancestry

KABASHI Edor, Paris, France

Development of zebrafish models for C9orf72, the major genetic cause in Amyotrophic Lateral Sclerosis and related neurological diseases

LEGAY Claire, Paris, France

Post-transcriptional control of Acetylcholine receptor mRNA; implications for neuromuscular diseases

LEGENDRE Pascal, Paris, France

Microglia instruct fate of embryonic neurons at the onset of developmental cell death in the embryonic spinal cord in vivo

MANUEL Marin, Paris, France

Is hyperexcitability protective or harmful in ALS?

MILLECAMPS Stéphanie, Paris, France

Genetics of Young Amyotrophic Lateral Sclerosis

MONANI Umrao, New York, Etats-Unis

Molecular mediators of the spinal muscular atrophy NMJ phenotype

NOBREGA Clevio, Coimbra, Portugal

Ataxin-2 as a new molecular target in Machado-Joseph disease: from translation regulation to disease alleviation

PEREIRA DE ALMEIDA Luis, Coimbra, Portugal

Activating autophagy to block Machado-Joseph disease progression

RIVAL Thomas, Marseille, France

Using *drosophila* as a model system to dissect the mechanisms by which mitochondrial fusion defect triggers neuronal dysfunctions in Charcot-Marie-Tooth type 2A disease

SCAMPS Frédérique, Montpellier, France

Role of the Ca²⁺ activated Cl⁻ channel, Anoctamin 6, in motoneuron pathophysiology

SORARU Gianni, Padoue, Italie

Skeletal muscle: target tissue to cure Spinal and Bulbar Muscular Atrophy (SBMA)

SORET Johann, Montpellier, France

Genome-wide identification of SMN-interacting mRNAs showing axonal localization defects in SMA

STROCHLIC Laure, Paris, France

MuSK frizzled-like domain at the neuromuscular junction: novel insight into pathophysiology and therapeutics for myasthenia

Commission : Cellules souches

Aides aux jeunes chercheurs post-doctorants

FRANCOIS Stéphanie, Milan, Italie

Unravelling differences between Satellite Cells and Mesoangioblasts: modulation of the Rho/ROCK pathway in the activation of Satellite Cells migration.

GIROUSSE Amandine, Toulouse, France

White adipose tissue: a stem/stromal cell provider involved in muscle regeneration?

STUELSATZ Pascal, Seattle, Etats-Unis

EOM satellite cells: high performance myo-engines for muscular dystrophy therapy

Financements de projets Tremplins

MORIN Xavier, Paris, France

Dynamic distribution of Mib1 during mitosis of motor neuron progenitors derived from mouse ES cells

NOTARNICOLA Cécile, Montpellier, France

Human reserve cells: a dynamic tool to discover genes involved in muscle stem cell quiescence

PLUN-FAVREAU Hélène, Londres, Royaume-Uni

Understanding the mechanism underpinning segregation of mitochondrial DNA mutation during somatic cell reprogramming

THORREZ Lieven, Kortrijk, Belgique

Tissue engineering of human muscle: proof of principle for using iPSC-derived myogenic precursor cells and a prevascularization strategy

Financements de projets

BIRCHMEIER Carmen, Berlin, Allemagne

Hes1 and quiescence in satellite cells

BOHL Delphine, Paris, France

Characterization of pathological defects in motor neurons derived from patients with Amyotrophic Lateral Sclerosis

BOIS Patrick, Poitiers, France

Control and modulation of myogenic differentiation of stem cells by using optogenetic approaches

CHAHINE Mohamed, Québec, Canada

Cardiac involvement in myotonic dystrophy type 1 disease: development of improved diagnoses and therapeutics

COMI Giacomo Pietro, Milan, Italie

Optimized transplantation of hiPSC derived LEX+CXCR4+VLA4+ neural stem cells as a therapy for SMARD1

FERNANDEZ Anne, Montpellier, France

Skeletal Muscle as a reservoir of multipotent adult stem cells.

HUGNOT Jean-Philippe, Montpellier, France

The niche of stem cells in the adult spinal cord: cellular diversity and molecular mechanisms underlying dormancy and activation

IMBRIANO Carol, Modène, Italie

NF-YA as a molecular switch with therapeutic potential in muscle regeneration

JAGLA Krzysztof, Clermont-Ferrand, France

A systems level cell-type specific approach to assess diversification of cell fates

KELLY Robert, Marseille, France

Investigation of the emergence of craniofacial muscle progenitor cells in pharyngeal mesoderm

KOISTINAHO Jari, Kuopio, Finlande

Human Model of Neuromuscular Junctions in the Research of Amyotrophic Lateral Sclerosis

MAIRE Pascal, Paris, France

Myogenic fate of satellite cells

MOUNIER Rémi, Villeurbanne, France

AMPKa1 as a regulator of adult muscle stem cell fate choice

PARLAKIAN Ara, Paris, France

Bcl11b/CTIP2, a newly identified transcriptional repressor: its role in cardiac hypertrophy and commitment of cardiac stem cells.

Commission : Thérapie Génique et/ou Cellulaire des Maladies Rares

Aides aux jeunes chercheurs post-doctorants

CHAPPERT Pascal, Paris, France

Cross-tolerance approaches for AAV-mediated muscle gene transfer

PETIT Lolita, Worcester, Etats-Unis

Prolonging vision in retinitis pigmentosa by AAV-mediated genetic modulation of the insulin/AKT/mTOR pathway

SANCHEZ-DUFFHUES Gonzalo, Leiden, Pays-Bas

Putting the brakes on fop: development of novel strategies to block heterotopic ossification

VACCA Ophelie, Orsay, France

AAV-Mediated Dystrophin-Dp71 Gene Therapy In The Central Nervous System

Financements de projets Tremplins

EVERS Melvin, Leiden, Pays-Bas

Targeting ataxin-1 in spinocerebellar ataxia type 1 (SCA1) patient-specific induced pluripotent stem cell-derived neurons

MENDONÇA Liliana, Coimbra, Portugal

Does the transplantation of mutant ataxin-3-depleted patient-derived NSC alleviates Machado Joseph disease (MJD)?

Financements de projets

ADRIOUCH Sahil, Rouen, France

Induction of immunological tolerance following AAV-mediated muscle gene transfer using bi-functional fusion proteins combining extracellular domains of CTLA-4 and PD-L1

BARON VAN EVERCOOREN Anne, Paris, France

Induced pluripotent stem cells to treat pelizaeus merzbacher disease

BELENGUER Pascale, Toulouse, France

Proof of principle of an original therapeutic strategy for a rare disease, dominant optic atrophy

BOSCH Fatima, Bellaterra, Espagne

AAV-mediated gene therapy for the treatment of MPSIIID (Sanfilippo D)

DAVOUST Jean, Paris, France

Gene transfer tolerance in combined liver and muscle rAAV gene therapy

DEGLON Nicole, Lausanne, Suisse

In vitro and in vivo gene editing using viral delivered CRISPR system for Huntington's disease

GRAY Steven, Chapel Hill, Etats-Unis

Aspartylglucosaminuria gene therapy using AAV vectors to target the CNS

KLEOPA Kleopas, Nicosia, Chypre

A gene therapy approach for treating CMT4C

LOPEZ Bernard, Villejuif, France

Stimulating homologous recombination for gene correction of monogenic diseases

NAVARRO Xavier, Barcelone, Espagne

Gene therapy targeting neuregulins for the treatment of amyotrophic lateral sclerosis

NOWAK Kristen, Perth, Australie

ACTA1 congenital myopathies: evaluating viral and gene therapy

PAGANI Franco, Trieste, Italie

Molecular mechanism and therapeutic activity of modified U1 snRNAs in Spinal Muscular Athrophy

TAYLOR Naomi, Montpellier, France

Intrathymic hematopoietic stem cell transplantation for the correction of severe combined immunodeficiency

Commission : Thérapie Pharmacologique des maladies neuromusculaires et Recherche Translationnelle

Aides aux jeunes chercheurs post-doctorants

DURAND Sebastien, Lyon, France

Characterization of INT6/EIF3E functions during Nonsense Mediated Decay (NMD) and development of new NMD inhibitors

SZTAL Tamar, Melbourne, Australie

Investigation of Therapies for Nemaline Myopathy

Financements de projets Tremplins

CAMARA Yolanda, Barcelone, Espagne

Novel therapeutic perspectives for mitochondrial DNA depletion and deletion syndrome due to defective dNTP homeostasis: The specific case of TK2 deficiency

GINESTE Charlotte, Marseille, France

In vivo investigation of skeletal muscle function after chronic administration of CsA in a mouse model of Mitochondrial MYopathy: a combined anatomical, metabolic and functional study using MRI and ³¹P-MRS

SPICHTY Martin, Lyon, France

Selective inhibition of heat-shock binding protein 1: A proof of concept towards a novel strategy to enhance stress response in pathological motor neurons.

SZELECHOWSKI Marion, Bordeaux, France

Evaluation of the therapeutic potential of the Bornavirus X protein and X-derived peptides in amyotrophic lateral sclerosis (ALS)

Financements de projets

AARTSMA-RUS Annemieke, Leiden, Pays-Bas

Cross-sectional study to assess detailed natural disease history of limb girdle muscular dystrophy mouse models

BOITARD Christian, Paris, France

A new model of myositis in Icos^{-/-} and Icosl^{-/-} NOD mice: from biomarkers to pathogenesis

D'ANTONIO Maurizio, Milan, Italie

Targeting Schwann cell proteostasis as a therapeutic strategy in Charcot-Marie-Tooth disease

DESAPHY Jean-François, Bari, Italie

Riluzole, lubeluzole and benzothiazolamine derivatives as new potent antimitotonic drugs

GIRARD Christian, Paris, France

New nonsense-mediated mRNA decay (NMD) inhibitor molecules

MATECKI Stefan, Montpellier, France

Dystrophin-deficient diaphragm dysfunction induced by mechanical ventilation in mdx mice.

NAMY Olivier, Orsay, France

Translational suppression of nonsense mutations found in DMD

PHYLACTOU Leonidas, Nicosia, Chypre

Developing miRNA serum-based biomarkers for Myotonic Dystrophy type 1

PREVITALI Stefano Carlo, Milan, Italie

Modulation of Jab1/p27 levels to rescue peripheral neuropathy and muscular dystrophy in Congenital Muscular Dystrophy type 1A.

ROSSI Daniela Maria, Pavia Italie

Assessing the in vivo efficacy of peptide therapeutics towards the progression of spinal muscular atrophy

T HOEN Peter, Leiden, Pays-Bas

Validation of serum biomarkers to monitor disease progression and response to therapy in DMD and other Muscular Dystrophies

ZAMMIT Peter, Londres, Royaume-Uni

Modelling FSHD as a tool for testing therapeutics

Commission : Médicale

Aides aux jeunes chercheurs post-doctorants

GARGUILO Marine, Garches, France

Impact of pre-phonation inspiratory volume on speech quality of neuromuscular patients requiring non invasive ventilation

Financements de projets

COSTEDOAT-CHALUMEAU Nathalie, Paris, France

Muscular diseases and pregnancy

LOFASO Frédéric, Garches, France

Validation of non-invasive non-volitional methods for monitoring respiratory muscle function in Duchenne muscular dystrophy

NECTOUX Juliette, Paris, France

Clinical Implementation of Noninvasive Prenatal Testing for Duchenne Muscular Dystrophies

SARIS Christiaan, Nijmegen, Pays-Bas

Evaluation of dysphagia in inclusion body myositis and oculopharyngeal muscle dystrophy by combining novel ultrasound and real-time MRI

WAHBI Karim, Paris, France

Venous thromboembolism in myotonic dystrophy type 1

Appel d'Offres Doctorants

ANGELIM Monara, Paris, France

Microglia regulate fate of embryonic sensory neurons at the onset of dorsal root ganglia formation in the embryonic spinal cord in vivo

BABSKI Hélène, Montpellier, France

Getting wired up for locomotion: the premotor interneuron/motoneuron connection in Drosophila

BERTIN Benjamin, Clermont Ferrand, France

Molecular and functional analyses of muscle diversification processes by cell type specific genomic approaches in Drosophila

CROISSANT Coralie, Pessac, France

Role of annexins in membrane repair of human skeletal muscle

DAHER Marie-Thérèse, Paris, France

Bcl11b/CTIP2, a newly identified transcriptional repressor: its role in cardiac hypertrophy and commitment of cardiac stem cells.

DE BONO Christopher, Marseille, France

Dissecting the mechanisms by which distinct muscle cell types arise in posterior cardiopharyngeal mesoderm.

DEWULF Melissa, Paris, France

Functional analysis of Cav3 mutations in muscular dystrophy diseases

DINCA Diana Mihaela, Paris, France

Pathophysiological impact of the CTG repeat expansion on neuronal and astroglial biology in DM1 brains

DIOUF Sarah, Toulouse, France

Decryption of the roles of CBP methylation in human primary myoblast differentiation: cross-talk between nuclear and mitochondrial genomes.

DOS SANTOS Matthieu, Paris, France

Genetic control of adult muscle fiber type

EL FISSI Najla, Marseille, France

Using drosophila as a model system to investigate how altered mitochondrial fusion triggers mitochondrial damages and neuromuscular disorders

GAZALAH Hussein, Fanar, Liban

Enigmatic perineuronal cells in the mouse and human spinal cord: properties, isolation and function

GRIMALDI Alexandre, Los Angeles, Etats-Unis

Regulation and morphogenesis of cranial muscle derivatives

- GUERIN Amandine**, Montpellier, France
Function of double-strain RNA-Binding Protein LIX1 and its interacting protein partner during digestive smooth muscle cell plasticity.
- HOVHANNISYAN Yeranuhi**, Paris, France
Cardiac modelling of myofibrillar myopathy using human pluripotent stem cells to explore cardiac pathogenesis and drug testing
- KHABOU Hanen**, Paris, France
Retinitis Pigmentosa: gene therapies to prevent and restore vision loss
- KUTCHUKIAN Candice**, Villeurbanne, France
Phosphoinositides and Ca²⁺ signaling in normal and diseased skeletal muscle
- LAVERGNE Guillaume**, Clermont-Ferrand, France
Studying homing behaviour of Drosophila Adult Muscle Precursor (AMP) cells using genome wide cell specific approaches
- MARSAC Roxane**, Bordeaux, France
Adenylosuccinate Lyase deficiency - from metabolic deficiency to muscle disease using C. elegans as model organism
- MATONTI Julia**, Nice, France
Investigating novel functions of the Kir2.1 potassium channels in muscle and during bone morphogenesis.
- MIAS-LUCQUIN Dominique**, Rennes, France
Dynamics and mechanics of the myopathy-related protein dystrophin in macromolecular complexes with filamentous partners
- MOUSSAOUI Nadir**, Saint-Priest En Jarez, France
Targeting mitochondria to improve muscle function in a mouse model of autosomal dominant centronuclear myopathy.
- NASSARI Sonya**, Paris, France
Involvement of CXCL12 and CXCL14 chemokines in connective tissue-mediated limb muscle morphogenesis.
- RAESS Matthieu**, Strasbourg, France
Deciphering the functional and molecular differences between MTM1 and MTMR2 to understand two neuromuscular diseases.
- SAMSON Camille**, Gif-Sur-Yvette, France
Structural analysis of the emerin-lamin complex mutated in Emery-Dreifuss muscular dystrophy
- SCIONTI Isabella**, Lyon, France
Epigenetics in muscle lipid metabolism
- SLEIMAN Yvonne**, Montpellier, France
Cardiac dysfunction in Duchenne Muscle Dystrophy children: pathophysiological role of type 2 ryanodine receptor through hiPSC-derived cardiomyocytes
- SUTCU Haser**, Paris, France
Implication of DNA Damage and Repair in Viability and Differentiation of Muscle Stem Cells
- TERRONE Sophie**, Lyon, France
Interplay between epigenetic marks and alternative splicing during myogenesis
- TEYSSIER Perrine**, La Tronche, France
Mechanisms of triad formation
- TEYSSOU Elisa**, Paris, France
In vitro and in vivo functional analysis of 2 genes identified in familial amyotrophic lateral sclerosis
- WATTIN Marion**, Villeurbanne, France
Comparative study of proteostasis during muscle degeneration in models for muscular dystrophies
- WURMSER Maud**, Paris, France
SIX homeoproteins and muscle stem cells properties

Appel d'Offres « Projets de recherche translationnelle sur l'ARN en tant que médicament et cible thérapeutique »

D'AMATI Giulia, Rome, Italie

Stabilization of tRNAs as a therapeutic strategy for diseases due to mutations in mt-tRNAs.

FRANCO Brunella, Pozzuoli (Naples), Italie

Modulation of miR181a/b as a new therapeutic approach for Leber hereditary optic neuropathy (LHON)

HUDA Ruksana, Galveston, Etats-Unis

Target specific antibody-siRNA conjugate therapy for experimental myasthenia

NAMY Olivier, Orsay, France

Translectin: A new termination codon readthrough inducer to expand therapeutics choices for nonsense genetic diseases

VAN ROON-MOM Willeke, Leiden, Pays-Bas

Final proof of concept for the advancement of antisense oligonucleotide treatment for SCA3 towards the clinic

Partenariats institutionnels

GACHE Vincent, Lyon, France

Soutien du projet de recherche du candidat ATIP-Avenir 2016: Interplay between cytoskeleton network regulation during muscle development and muscle function

Partenariats associatifs

SMA EUROPE

ALLAIN Frédéric, Zurich, Suisse

Seeking small molecules that stabilize protein-RNA interactions to cure Spinal Muscular Atrophy

GARCIA-LOPEZ Amparo, Post Doctorant, Genève, Suisse

Using RNA secondary structure as a therapeutic target for Spinal Muscular Atrophy: a new drug discovery approach

Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques (ARSEP), Call for proposal 2016

"Myelin: from lesion to reparation"

STANKOFF Bruno, Paris, France

Remyelination at the early stage of Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation

CLEMENTE LOPEZ Diego, Toledo, Espagne

Myeloid-derived suppressor cells and disease aggressiveness: a novel cell therapy to accelerate myelin repair in multiple sclerosis

IFCAH, Paris, France

GUASTI Leonardo, Londres, Angleterre

Study of CAH adrenocortical cells reprogrammed from urine: a step towards a novel cell therapy

Vaincre les Maladies Lysosomiales (VML), Massy, France

ROUVIERE Laura, Post Doctorant, Paris, France

Gene transfer in the murine model of Sandhoff disease using a specific AAV9 vector

Vaincre la Mucoviscidose (VLM),

CADARS-TAULAN Magali, Montpellier, France

Détermination des éléments cis- et trans-régulateurs dans le contrôle de l'expression du gène CFTR en contexte physiologique et pathologique

MIDOUX Patrick, Orléans, France

Transfert de gènes par des vecteurs synthétiques : Construction d'un plasmide CFTR optimisé pour son transport dans le noyau des cellules épithéliales pulmonaires CF

MONTIER Tristan, Brest, France

Développement et optimisation de formulations lipidiques originales pour la transfection pulmonaire par aérosolisation sur modèles murins cf-/-

HONG BOULANGER Saw See, Lyon, France

Vésicules extracellulaires (microvésicules et exosomes) comme vecteurs du CFTR: mode de délivrance, biodistribution et ciblage tissulaire in vivo

Projets soumis en dehors du calendrier AO ou sortis de l'AO pour des raisons de PI

GOMES-PEREIRA Mario, Paris, France

DM1 disease mechanisms in the central nervous system: from brain cell-specific pathogenesis to misregulated glutamate homeostasis

GOURDON Geneviève, Paris, France

Mechanisms of CTG repeat contractions in unusual DM1 families

GOURDON Geneviève, Paris, France

CDM features and mechanisms in the DMSXL mouse model for DM1

MARCELLE Christophe, Clayton, Australie

Muscle fusion as a delivery mechanism to repair ailing muscles from heritable muscle diseases

MELKI Judith, Le Kremlin-Bicêtre, France

New Genomics Approaches in Neuromuscular Disorders: Applications in the Identification of New Disease Causing Genes and Mechanisms, of Revertant Somatic Mosaicism and in Undiagnosed Patients

SERGEANT Nicolas, Paris, France

Modified MBNL constructs for a gene therapy targeting nuclear expanded-CUG repeats to counteract toxic RNA gain-of-function in Myotonic Dystrophy

ZEITZ Christina, Paris, France

Développement d'une thérapie génique pour restaurer la fonction de GRM6/mGluR6 dans la cécité nocturne congénitale stationnaire

ACTIONS STRATEGIQUES

Projets stratégiques

GUEDAT Philippe, Nantes, France

Pre-clinical and clinical development of IFB-088, a new chemical entity to treat Charcot-Marie-Tooth disease

LAPORTE Jocelyn, Illkirch, France

Genetic bases, pathomechanisms and preclinical developments in congenital myopathies

MUNTONI Francesco, Londres, Royaume Uni

Advances in oligonucleotide-mediated exon skipping for DMD and related disorders - WP3 - Natural history extension

PORTE-THOME Florence, Plan les Ouates, Suisse

Translational studies to evaluate the efficacy of Rimeporide, a NHE-1 inhibitor, in patients with Duchenne Muscular Dystrophy

ROTIG Agnès, Paris, France

An integrated approach for MITOchondrial disorder THERApeutics from yeasts and worms to humans

SIMONELIG Martine, Montpellier, France

Towards a clinical trial for OPMD

Plateformes stratégiques

GOTTRAND Frédéric, Lille, France

Financement CIC Lille

Pôles stratégiques

LEVY Nicolas, Marseille, France

Translational Research in Marseille: towards Therapeutic Development for Rare Diseases

RELAIX Frédéric, Créteil, France

TRANSLAMUSCLE: An integrated translational program from basic research to biotherapies in stem cells and molecular medicine of the neuromuscular system

SCHAEFFER Laurent, Lyon, France

Alliance MyoNeurALP - a research network dedicated to neuromuscular disorders

Structures stratégiques

FONDATION MALADIES RARES, Paris, France

Subvention 2016

GENOPOLE, Evry, France

Participation financière de l'AFM au budget 2016 du GIP GENOPOLE

Outils stratégiques

BASSEZ Guillaume, Créteil, France

DM-Scope International French-Quebec Myotonic Dystrophy Registry

DESGUERRE Isabelle, Paris, France

A national clinical (and genetic) database for dystrophinopathies

SACCONI Sabrina, Nice, France

French National Registry for FacioScapuloHumeral muscular Dystrophy (FSHD) (projet 1)

SACCONI Sabrina, Nice, France

French National FSHD patient registry for clinical trial planning and translational research (projet 2)

AUTRES ACTIONS

Manifestations scientifiques (congrès, colloques)

COLLOQUE JEUNES CHERCHEURS, Lyon, France

Colloque Jeunes Chercheurs 2016 - 17 mars 2016 - Congrès Myologie 2016

CORNELISON Dawn D., Columbia – MO, Etats-Unis

FASEB Science Research Conference on Skeletal Muscle Satellite Cells and Regeneration

DUSSAULE Jean-Claude, Paris, France

"Physiology and inherited rare diseases: When physiology meets the genes" and "PHOX2B and Ondine's Curse, a story from gene to disease"

GOIZET Cyril, Bordeaux, France

Organization of the "14èmes Journées de la Société Française de Myologie"

JAMAR Gaëlle, Paris, France

Congrès Annuel de la Société Française de Thérapie Cellulaire et Génique

JAMAR Gaëlle, Paris, France

Annual congress of the European Society for Gene and Cell Therapy, Public Engagement Day

KALATSIS Vasiliki, Montpellier, France

Vision beyond the genome (a conference of the European Union Marie-Curie Initial Training Network, EyeTN)

KINOSHITA June, Lexington, Etats-Unis

FSHD Connect International Research Conference and Patient Conference

LEGAY Claire, Paris, France

XVth International Symposium on Cholinergic Mechanisms

MATECKI Stefan, Montpellier, France

Organisation of the 45th congress of the European Musculat Conference

MUSARO Antonio, Rome, Italie

IIM-Myology meeting: focus on pathogenesis of rare diseases and therapies

TAILLANDIER Daniel, St Genès Campanelle, France

7th Proteasomes & Autophagy Workshop

Plateforme non stratégique

CARRE Monique, Mézilles, France